Alla studier
RekryteringFAS3INTERVENTIONELL

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

This research study is for adults (18 and over) with a condition called Phenylketonuria (PKU). We are testing a new tablet medicine, JNT-517, to see if it's safe to use, how well it helps control PKU, and how your body reacts to it. You will either receive the new medicine or a 'dummy' tablet (placebo) without knowing which one, and there's a good chance you'll get the real medicine during the first part of the study. After about six weeks, everyone continuing in the study will receive JNT-517 for many months. Taking part will involve regular check-ups, keeping a food diary, and occasionally collecting urine samples. The study could last for about 400 days in total.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Inskrivningsmål
120
Starta
20 Oct 2025
Beräknad slutförande
01 Apr 2028

Vad handlar denna studie om?

This study is designed to explore a new tablet medicine called JNT-517 for people living with Phenylketonuria, often called PKU. PKU is a lifelong condition that affects how the body breaks down a substance found in food, called phenylalanine. If not managed properly, high levels of phenylalanine can lead to health problems.

The main aim of this study is to find out if JNT-517 is a safe and effective way to help manage PKU in adults. We also want to understand how your body processes this new medicine. We're especially interested in how it affects your phenylalanine levels. By carefully studying JNT-517, we hope to contribute to new ways of helping people with PKU live healthier lives.

This important stage of research, called Phase 3, means the medicine has already been tested in smaller groups and shown some promise. Now, it's being tested in a larger group of people to confirm these findings and gather more information before it could potentially become widely available.

Viktiga punkter

  • This study is testing a new PKU tablet, JNT-517, in adults.
  • It aims to check the medicine's safety and how well it works.
  • You might take JNT-517 or a dummy pill (placebo) at first.
  • Participation involves regular check-ups, keeping a food diary, and taking the study medicine twice daily.
  • The total study time could be around 400 days.
  • Du kan sluta delta när som helst.

Vem kan vara berättigad?

To join this study, you need to be an adult (18 years old or over) with a formal diagnosis of PKU. Your phenylalanine levels in your blood also need to be above a certain level during the screening checks.

If you are currently taking other medicines for PKU, such as sapropterin or special amino acid supplements, you might still be able to join, but your dose must have been stable for at least 4 weeks before the study starts and stay stable throughout. If you've been on a medicine called pegvaliase, you would need to have stopped taking it at least 4 weeks before screening.

You also need to be willing and able to stick to a stable PKU diet, and be able to adjust it if needed during the study. There are also specific requirements for women who could become pregnant, including using effective birth control methods.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 18 år eller äldre?
  2. Do you have a diagnosis of PKU?
  3. Are your phenylalanine levels typically above a certain level?
  4. Are you able and willing to maintain a stable PKU diet?
  5. If you might become pregnant, are you willing to use two effective forms of birth control during the study?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, you'll first have a screening period that could last up to 35 days. This is to make sure your diet is stable and your phenylalanine levels meet the study's requirements.

After screening, you'll take either JNT-517 or a placebo (dummy pill) twice a day for about 365 days. In the first six weeks, there's a 2 in 3 chance you'll receive JNT-517. After that, if you continue, you will definitely receive JNT-517, but at one of two possible doses, for an additional 46 weeks.

Throughout the study, you'll have regular check-ups, either by visiting a clinic or having a nurse come to your home. You'll also be asked to collect urine samples at home and bring them to the clinic on specific days. For 3 days before each study visit, you'll need to keep a food diary. The total time you could be involved in the study is up to 400 days.

Potentiella risker och fördelar

Taking part in any medical study has potential benefits and risks. The potential benefit of this study is that JNT-517 might help manage your PKU more effectively. However, it's also possible you might not experience any direct benefits, especially if you are in the placebo group initially. As with any new medicine, there could be side effects, which the study will carefully monitor. You will be told about all known possible side effects. Remember, joining this study is completely voluntary, and you are free to withdraw at any time without giving a reason, and it will not affect your usual medical care.

Platser (25)

  • University of California Los Angeles (UCLA) School of Medicine
    Verifierat postnummer
    Los Angeles, USA· Rekrytering
  • University of Florida (UF) Health Shands Hospital
    Verifierat postnummer
    Gainesville, USA· Rekrytering
  • University of South Florida
    Verifierat postnummer
    Tampa, USA· Rekrytering
  • Ann & Robert H. Lurie Barnsjukhus i Chicago
    Verifierat postnummer
    Chicago, USA· Rekrytering
  • Oregon Health and Science University
    Verifierat postnummer
    Portland, USA· Rekrytering
  • University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh
    Verifierat postnummer
    Pittsburgh, USA· Rekrytering
  • Vanderbilt University Medical Center
    Verifierat postnummer
    Nashville, USA· Rekrytering
  • University of Texas Southwestern
    Verifierat postnummer
    Dallas, USA· Rekrytering
  • University of Texas Health (UTHealth) Science Center at Houston
    Verifierat postnummer
    Houston, USA· Rekrytering
  • Utah Health - The University of Utah Hospital
    Verifierat postnummer
    Salt Lake City, USA· Rekrytering
  • Royal Adelaide Hospital
    Verifierat postnummer
    Adelaide, Australien· Rekrytering
  • Kungliga Melbourne-sjukhuset
    Verifierat postnummer
    Parkville, Australien· Rekrytering

Vanliga frågor

What is Phenylketonuria (PKU)?

PKU is a genetic condition where your body can't properly process a substance called phenylalanine, which is found in many foods. If not managed, it can build up and cause health problems.

What is JNT-517?

JNT-517 is a new tablet medicine being tested to help control phenylalanine levels in adults with PKU.

Vad är en 'placebo'?

A placebo is a 'dummy' tablet that looks like the study medicine but contains no active drug. It helps researchers compare the effects of the new medicine.

Will I know if I'm taking JNT-517 or the placebo?

No, you won't know initially. This is called 'blinding' and helps ensure the study results are fair. Everyone who continues after the first six weeks will receive JNT-517.

Hur länge kommer studien att pågå?

Including screening, your participation could last for up to 400 days, which is just over a year.

Hur du får reda på mer

Otsuka Call Center

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Study of JNT-517 in Participants With Phenylketonuria (PKU…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.